Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients

Table 4

Effects of EPA on blood fatty acids composition.

		Normolipidemic (𝑛=18)	Hyperlipidemic (𝑛=16)
			0M	1M	3M
Myristic, C14:0	𝜇g/mL	21 ± 12	31 ± 11	33 ± 19	32 ± 19
Palmitic, C16:0	μg/mL	668 ± 156	989 ± 265*	986 ± 404*	913 ± 390
Palmitoleic, C16:1n-7	μg/mL	52 ± 15	82 ± 38*	88 ± 52	79 ± 49
Stearic, C18:0	μg/mL	221 ± 41	272 ± 66*	273 ± 70*	265 ± 68
Oleic, C18:1n-9	μg/mL	617 ± 177	907 ± 249**	856 ± 439	783 ± 410
Linoleic, LA C18:2n-6	μg/mL	935 ± 200	1203 ± 228**	1060 ± 248	996 ± 222^†
γ-Linolenic, GLA C18:3n-6	μg/mL	8.3 ± 5.6	11.7 ± 4.0	8.8 ± 2.8	8.3 ± 3.7^†
α-Linolenic acid, ALA C18:3n-3	μg/mL	27 ± 21	38 ± 15	37 ± 14	37 ± 15
Dihomo-γ-linolenic acid, DHGLA C20:3n-6	μg/mL	34 ± 10	52 ± 15**	35 ± 13^††	32 ± 10^†††
Arachidonic acid, AA C20:4n-6	μg/mL	182 ± 41	209 ± 40	197 ± 45	164 ± 45^†
Eicosapentaenoic, EPA C20:5n-3	μg/mL	45 ± 26	52 ± 26	161 ± 49^***†††	180 ± 55^***†††
Docosahexaenoic, DHA C22:6n-3	μg/mL	122 ± 46	159 ± 60	162 ± 68	157 ± 65
EPA/AA		0.24 ± 0.12	0.25 ± 0.12	0.84 ± 0.29^***†††	1.16 ± 0.46^***†††

Mean ± SD, *𝑃<0.05, **𝑃<0.01, ***𝑃<0.001 versus normolipidemic, ^†𝑃<0.05, ^†††𝑃<0.001 versus 0M. 0M, 1M, and 3M: baseline and 1 and 3 months after EPA treatment.